Dosing Frequency and Formulary Decisions for Bispecific Antibodies

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Issam S. Hamadeh, PharmD, BCPS, BCOP

Key Takeaways

Weekly dosing may provide consistent therapeutic levels, while biweekly dosing reduces hospital visits, affecting patient convenience and healthcare resource allocation.
Formulary decisions should evaluate efficacy, safety profiles, cost-effectiveness, and integration potential into existing treatment regimens.
Patient-specific factors, including comorbidities and previous treatment responses, are crucial in determining the appropriate dosing schedule and formulary inclusion.

Panelists discuss how when selecting between weekly and biweekly dosing schedules for talquetamab and teclistamab in multiple myeloma treatment, health care institutions must carefully weigh factors like patient convenience, monitoring requirements, resource utilization, and total cost of care alongside clinical outcomes to determine optimal treatment pathways for both patient and health system benefits.

EP: 1.Current Landscape of Bispecific Therapies for RRMM

EP: 2.Operationalizing Bispecific Therapy and the Impact of CAR-T Advancements on Sequencing

EP: 3.Best Practices for Standardizing Step-Up Dosing

Now Viewing

EP: 4.Dosing Frequency and Formulary Decisions for Bispecific Antibodies

Video content above is prompted by the following

Specifically, for talquetamab and teclistamab, how has your institution standardized selection of weekly or biweekly dosing, and how do these different dosing frequencies differ in terms of impact on the health system and patient?
What additional factors should be considered when making formulary decisions regarding the 3 currently available bispecific antibodies?